Robert Klitzman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Robert Klitzman has a total of 137 co-authors. Here are the top co-authors by number of shared publications:
Elizaveta Garbuzova
Bioethics Program, Columbia University, New York, NY, USA
10 shared publicationsGabrielle Di Sapia Natarelli
Bioethics Program, Columbia University, New York, NY, USA
10 shared publicationsJay Al-Hashimi
Bioethics Program, Columbia University, New York, NY, USA
10 shared publicationsStephanie Sinnappan
Bioethics Program, Columbia University, New York, NY, USA
9 shared publicationsWendy Chung
Department of Pediatrics, Columbia University, New York, New York
8 shared publicationsPaul S. Appelbaum
Psychiatry, Medicine and Law, Center for Law, Ethics and Psychiatry Columbia University Irving Medical Center New York New York USA
7 shared publications
Latest Publications
- 16 September 2026
- Published by Oxford University Press (OUP) in Academic Medicine
Academic medical centers implementing new Medical Aid in Dying (MAiD) laws: challenges and solutions
New York and additional jurisdictions are now joining others in legalizing Medical Aid in Dying (MAiD), but academic medical centers and clinicians are, consequently, confronting dilemmas regarding whether to provide it, and if so, how. Institutions must decide what processes to establish if patients inquire about MAiD, which specific clinicians within an institution should evaluate patients for eligibility and capacity, and prescribe MAiD medications, how to communicate about the new law with patients and local communities, how to educate medical and other students and staff appropriately, and how to make these decisions. The contexts of state laws, hospital, clinicians, patients, and local communities all vary in ways that can affect these new institutional practices and policies. Though a few jurisdictions have addressed MAiD in the past, use has been increasing and attitudes changing, and the contexts of different states and their relevant laws vary considerably. For example, though some states require that patients alone, not clinicians, raise the topic of MAiD, others allow clinicians to broach the topic as well, posing challenges. These issues have critical implications for governmental and institutional policies, practice, research and education. This paper provides suggestions for how institutions should address these challenges—by establishing as early as possible a multidisciplinary working group, including providers (eg, from palliative care, psychiatry, nursing and social work), compliance, other administrative, legal, and ethics stakeholders. Hospitals should establish and disseminate clear step-by-step policies and procedures, including standardized electronic health record templates, and develop research protocols to assess the effects of implementation. Institutions should also provide and organize structured “debriefs” after initial cases (to examine what went well or not) and/or periodic case conferences among clinicians performing MAiD, and mentorship in providing and prescribing MAiD, offering support, in part due to moral distress and other concerns that can emerge.
- 16 September 2026
- Published by Oxford University Press (OUP) in Academic Medicine
Academic medical centers implementing new Medical Aid in Dying (MAiD) laws: challenges and solutions
New York and additional jurisdictions are now joining others in legalizing Medical Aid in Dying (MAiD), but academic medical centers and clinicians are, consequently, confronting dilemmas regarding whether to provide it, and if so, how. Institutions must decide what processes to establish if patients inquire about MAiD, which specific clinicians within an institution should evaluate patients for eligibility and capacity, and prescribe MAiD medications, how to communicate about the new law with patients and local communities, how to educate medical and other students and staff appropriately, and how to make these decisions. The contexts of state laws, hospital, clinicians, patients, and local communities all vary in ways that can affect these new institutional practices and policies. Though a few jurisdictions have addressed MAiD in the past, use has been increasing and attitudes changing, and the contexts of different states and their relevant laws vary considerably. For example, though some states require that patients alone, not clinicians, raise the topic of MAiD, others allow clinicians to broach the topic as well, posing challenges. These issues have critical implications for governmental and institutional policies, practice, research and education. This paper provides suggestions for how institutions should address these challenges—by establishing as early as possible a multidisciplinary working group, including providers (eg, from palliative care, psychiatry, nursing and social work), compliance, other administrative, legal, and ethics stakeholders. Hospitals should establish and disseminate clear step-by-step policies and procedures, including standardized electronic health record templates, and develop research protocols to assess the effects of implementation. Institutions should also provide and organize structured “debriefs” after initial cases (to examine what went well or not) and/or periodic case conferences among clinicians performing MAiD, and mentorship in providing and prescribing MAiD, offering support, in part due to moral distress and other concerns that can emerge.
- Open Access
- 24 August 2026
- Published by Springer Nature in AI and Ethics
- Vol. 6 (5) , 474
Ethics consultants’ perspectives on the use of artificial intelligence in ethical decision-making for patients incapacitated with no evident advance directives or surrogates: a qualitative study
As artificial intelligence (AI) tools are increasingly integrated into healthcare settings, their application to ethically complex care decisions for patients who lack decision-making capacity and identifiable surrogates remains largely unexplored. This study explored ethics consultants’ perspectives on the use of artificial intelligence (AI) in ethical and clinical decision-making for patients who are incapacitated with no evident advance directives or surrogates (INEADS). We conducted a qualitative study using in-depth semi-structured interviews with 19 ethics consultants across nine U.S. states, analyzed using thematic analysis. Three themes were generated. Theme 1, Human Accountability as a Non-Negotiable Boundary, captured ethical concerns including clinician accountability, AI’s inability to capture individual context, and algorithmic bias risk. Theme 2, Designing AI That Reflects the Complexity of INEADS Care, identified requirements for high-quality training data, interdisciplinary development teams, and explainability. Theme 3, A Conditional and Constructive Vision for AI as Supportive Tool, described applications encompassing surrogate identification, goals-of-care facilitation, longitudinal decisional pattern review, and individualized prognostication. Participants framed AI as a resource to support rather than replace human moral judgment, raised concerns about algorithmic bias and institutional variation, and articulated a constructive vision grounded in prior natural language processing work identifying INEADS patients across care settings. Ethics consultants expressed conditional acceptance of AI in INEADS care when used to support, not replace, accountable human judgment. Findings highlight the need for equity-centered design, transparent communication of data limitations, interdisciplinary development, and ethics consultant involvement in validation before clinical implementation.
- 24 August 2026
- Published by Springer Nature in AI and Ethics
- Vol. 6 (5) , 474
Open AccessEthics consultants’ perspectives on the use of artificial intelligence in ethical decision-making for patients incapacitated with no evident advance directives or surrogates: a qualitative study
As artificial intelligence (AI) tools are increasingly integrated into healthcare settings, their application to ethically complex care decisions for patients who lack decision-making capacity and identifiable surrogates remains largely unexplored. This study explored ethics consultants’ perspectives on the use of artificial intelligence (AI) in ethical and clinical decision-making for patients who are incapacitated with no evident advance directives or surrogates (INEADS). We conducted a qualitative study using in-depth semi-structured interviews with 19 ethics consultants across nine U.S. states, analyzed using thematic analysis. Three themes were generated. Theme 1, Human Accountability as a Non-Negotiable Boundary, captured ethical concerns including clinician accountability, AI’s inability to capture individual context, and algorithmic bias risk. Theme 2, Designing AI That Reflects the Complexity of INEADS Care, identified requirements for high-quality training data, interdisciplinary development teams, and explainability. Theme 3, A Conditional and Constructive Vision for AI as Supportive Tool, described applications encompassing surrogate identification, goals-of-care facilitation, longitudinal decisional pattern review, and individualized prognostication. Participants framed AI as a resource to support rather than replace human moral judgment, raised concerns about algorithmic bias and institutional variation, and articulated a constructive vision grounded in prior natural language processing work identifying INEADS patients across care settings. Ethics consultants expressed conditional acceptance of AI in INEADS care when used to support, not replace, accountable human judgment. Findings highlight the need for equity-centered design, transparent communication of data limitations, interdisciplinary development, and ethics consultant involvement in validation before clinical implementation.
- 11 August 2026
- Published by BMJ in Journal of Medical Ethics
Preparing for public discussions about the ethics of extending the 14-Day Rule: challenges and questions
Recently, the possibility of extending the so-called 14-Day Rule on human embryonic research has received increased attention, but many ethical, legal, scientific and logistical questions about doing so remain. When the 14-Day Rule was developed in 1979, human embryos could only be cultured for 3–5 days. Recently, embryos have been cultured for up to 13 or 14 days, which has the potential to provide important health benefits. Statements advocating extending the Rule have all stipulated that public engagement is essential. But crucial challenges arise, which have received relatively little attention, regarding specifically what and how to communicate about these controversial topics to policymakers, journalists and the public—what precisely to convey, how exactly such public discussions should occur, what content such communication should include, what obstacles may emerge and how best to respond to these barriers. Particular ethical, attitudinal, psychological, political, historical, educational and logistical obstacles emerge. Terms other than embryo ‘destruction’, for instance, may help. Empirical survey research is urgently needed to comprehend how policymakers and the public view and understand these issues and what educational approaches will be most effective. This paper examines challenges that emerge, suggests ways of addressing these and highlights needs for enhancing education, communication and literacy concerning relevant scientific and ethical issues. The enactment of ethically informed policy requires attention to not only what policies to pursue but how to communicate about these to stakeholders. Advocates for extensions of the Rule should recognise and begin to address these challenges as soon as possible.
- 11 August 2026
- Published by BMJ in Journal of Medical Ethics
Preparing for public discussions about the ethics of extending the 14-Day Rule: challenges and questions
Recently, the possibility of extending the so-called 14-Day Rule on human embryonic research has received increased attention, but many ethical, legal, scientific and logistical questions about doing so remain. When the 14-Day Rule was developed in 1979, human embryos could only be cultured for 3–5 days. Recently, embryos have been cultured for up to 13 or 14 days, which has the potential to provide important health benefits. Statements advocating extending the Rule have all stipulated that public engagement is essential. But crucial challenges arise, which have received relatively little attention, regarding specifically what and how to communicate about these controversial topics to policymakers, journalists and the public—what precisely to convey, how exactly such public discussions should occur, what content such communication should include, what obstacles may emerge and how best to respond to these barriers. Particular ethical, attitudinal, psychological, political, historical, educational and logistical obstacles emerge. Terms other than embryo ‘destruction’, for instance, may help. Empirical survey research is urgently needed to comprehend how policymakers and the public view and understand these issues and what educational approaches will be most effective. This paper examines challenges that emerge, suggests ways of addressing these and highlights needs for enhancing education, communication and literacy concerning relevant scientific and ethical issues. The enactment of ethically informed policy requires attention to not only what policies to pursue but how to communicate about these to stakeholders. Advocates for extensions of the Rule should recognise and begin to address these challenges as soon as possible.
- 5 September 2025
- Published by Springer Nature in Journal of Community Genetics
- Vol. 16 (6) , 799-812
Ambiguities faced by parents who received a genetic diagnosis for autistic offspring with intellectual disabilities
Genetic testing is now routinely recommended for autism and/or intellectual disability (ID), but how parents deal with the uncertainties that may be involved has not been explored. We interviewed 28 parents who had received results identifying de novo genetic variants responsible for their offspring’s autism. Parents faced six broad types of ambiguities concerning: cause of the de novo variant, likelihood of medical manifestations, children’s future independence and support needs, availability of future medical benefits/treatments, potential social benefits and potential social harms. These ambiguities prompted anxiety/stress. Parents tried to manage these uncertainties in several ways: focusing on the child’s immediate needs, seeking more information, seeking bases of comparison in other children, monitoring for future symptoms (and often enlisting others to do so), seeking metaphors and conceptual frameworks to understand uncertainties, making and accepting trade-offs, and participating in research. Several factors influence these uncertainties and responses, including age/life-stage of the child, psychological factors, concerns about the future of the broader healthcare and insurance systems, potential differences due to geography (e.g., local variations in medical, social and educational services available) and scientific background and literacy. Members of a couple also often perceive and respond to these issues differently. These data, the first to examine the ambiguities that arise when receiving genetic diagnoses for their autistic offspring with ID, reveal the key roles of several social factors and have important implications for future research, education of families, and training and practice of healthcare providers, teachers, social service agencies, policymakers and others.
- 5 September 2025
- Published by Springer Nature in Journal of Community Genetics
- Vol. 16 (6) , 799-812
Ambiguities faced by parents who received a genetic diagnosis for autistic offspring with intellectual disabilities
Genetic testing is now routinely recommended for autism and/or intellectual disability (ID), but how parents deal with the uncertainties that may be involved has not been explored. We interviewed 28 parents who had received results identifying de novo genetic variants responsible for their offspring’s autism. Parents faced six broad types of ambiguities concerning: cause of the de novo variant, likelihood of medical manifestations, children’s future independence and support needs, availability of future medical benefits/treatments, potential social benefits and potential social harms. These ambiguities prompted anxiety/stress. Parents tried to manage these uncertainties in several ways: focusing on the child’s immediate needs, seeking more information, seeking bases of comparison in other children, monitoring for future symptoms (and often enlisting others to do so), seeking metaphors and conceptual frameworks to understand uncertainties, making and accepting trade-offs, and participating in research. Several factors influence these uncertainties and responses, including age/life-stage of the child, psychological factors, concerns about the future of the broader healthcare and insurance systems, potential differences due to geography (e.g., local variations in medical, social and educational services available) and scientific background and literacy. Members of a couple also often perceive and respond to these issues differently. These data, the first to examine the ambiguities that arise when receiving genetic diagnoses for their autistic offspring with ID, reveal the key roles of several social factors and have important implications for future research, education of families, and training and practice of healthcare providers, teachers, social service agencies, policymakers and others.
- 28 May 2025
- Published by Cambridge University Press (CUP) in Journal of Law, Medicine & Ethics
- Vol. 53 (2) , 221-226
Gestational Surrogacy, the Pope, and Needs for Regulations
As surrogacy grows, many states and countries are enacting or considering relevant regulations, while others oppose it. Ethical, legal and policy questions arise: how to balance the rights of various kinds of parents (e.g., heterosexual and same-sex couples and single individuals) against the rights and well-being of surrogates. Concerns include risks of exploitation, autonomy, benefits of enabling prospective parents to create loving families, and mitigating possible harms through regulations. Though a few instances of abuse have been reported in developing countries, these do not appear to have occurred in developed countries, where robust regulations exist. The limited data available on surrogates in general (i.e., including traditional and non-commercial surrogacy) do not suggest exploitation or trafficking. In 2021, New York State enacted robust regulations allowing commercial surrogacy. Subsequent competing bills have sought to loosen or enhance certain restrictions. These regulations may be a model for commercial surrogacy regulations elsewhere, but certain ethical, legal and policy questions remain (e.g., where to draw the line to prevent trafficking). Additional data and exploration of these challenges are crucial
- 28 May 2025
- Published by Cambridge University Press (CUP) in Journal of Law, Medicine & Ethics
- Vol. 53 (2) , 221-226
Gestational Surrogacy, the Pope, and Needs for Regulations
As surrogacy grows, many states and countries are enacting or considering relevant regulations, while others oppose it. Ethical, legal and policy questions arise: how to balance the rights of various kinds of parents (e.g., heterosexual and same-sex couples and single individuals) against the rights and well-being of surrogates. Concerns include risks of exploitation, autonomy, benefits of enabling prospective parents to create loving families, and mitigating possible harms through regulations. Though a few instances of abuse have been reported in developing countries, these do not appear to have occurred in developed countries, where robust regulations exist. The limited data available on surrogates in general (i.e., including traditional and non-commercial surrogacy) do not suggest exploitation or trafficking. In 2021, New York State enacted robust regulations allowing commercial surrogacy. Subsequent competing bills have sought to loosen or enhance certain restrictions. These regulations may be a model for commercial surrogacy regulations elsewhere, but certain ethical, legal and policy questions remain (e.g., where to draw the line to prevent trafficking). Additional data and exploration of these challenges are crucial
- 9 January 2025
- Published by Wolters Kluwer Health in Journal of the Association of Nurses in AIDS Care
- Vol. 36 (3) , 227-236
Updating an HIV Knowledge Questionnaire With Pre-exposure Prophylaxis Through Expert Opinions in the United States Using Delphi Methodology: A Qualitative Study
Our study was designed to update the HIV Knowledge Questionnaire by incorporating pre-exposure prophylaxis (PrEP) knowledge questions, as previous HIV knowledge tools lack this focus. Four rounds of Delphi surveys were conducted with 47 expert participants, each with extensive HIV-related expertise (mean experience: 18.94 years). Expert participants rated item relevance on a scale of 0–3 and provided feedback. An item was removed if over 70% scored it two or less. The process continued until consensus was reached, defined as 80% of items scoring above two by more than 70% of expert participants, with no new suggestions. The final measure included 31 items covering general HIV knowledge, transmission modes, treatment, risk, and PrEP definitions, types, and dosages. Future research is essential to validate this tool for research and clinical settings, ensuring it accurately measures patients' diverse knowledge levels.
- 9 January 2025
- Published by Wolters Kluwer Health in Journal of the Association of Nurses in AIDS Care
- Vol. 36 (3) , 227-236
Updating an HIV Knowledge Questionnaire With Pre-exposure Prophylaxis Through Expert Opinions in the United States Using Delphi Methodology: A Qualitative Study
Our study was designed to update the HIV Knowledge Questionnaire by incorporating pre-exposure prophylaxis (PrEP) knowledge questions, as previous HIV knowledge tools lack this focus. Four rounds of Delphi surveys were conducted with 47 expert participants, each with extensive HIV-related expertise (mean experience: 18.94 years). Expert participants rated item relevance on a scale of 0–3 and provided feedback. An item was removed if over 70% scored it two or less. The process continued until consensus was reached, defined as 80% of items scoring above two by more than 70% of expert participants, with no new suggestions. The final measure included 31 items covering general HIV knowledge, transmission modes, treatment, risk, and PrEP definitions, types, and dosages. Future research is essential to validate this tool for research and clinical settings, ensuring it accurately measures patients' diverse knowledge levels.
- 21 April 2024
- Published by Taylor & Francis in AJOB Empirical Bioethics
- p. 1-18
Views of Genetic Testing for Autism Among Autism Self-Advocates: A Qualitative Study
Autism self-advocates' views regarding genetic tests for autism are important, but critical questions about their perspectives arise. We interviewed 11 autism self-advocates, recruited through autism self-advocacy websites, for 1 h each. Interviewees viewed genetic testing and its potential pros and cons through the lens of their own indiviudal perceived challenges, needs and struggles, especially concerning stigma and discrimination, lack of accommodations and misunderstandings from society about autism, their particular needs for services, and being blamed by others and by themselves for autistic traits. Their views of genetic testing tended not to be binary, but rather depended on how the genetic test results would be used. Interviewees perceived pros of genetic testing both in general and with regard to themselves (e.g., by providing "scientific proof" of autism as a diagnosis and possibly increasing availability of services). But they also perceived disadvantages and limitations of testing (e.g., possible eugenic applications). Participants distinguished between what they felt would be best for themselves and for the autistic community as a whole. When asked if they would undergo testing for themselves, if offered, interviewees added several considerations (e.g., undergoing testing because they support science in general). Interviewees were divided whether a genetic diagnosis would or should reduce self-blame, and several were wary of testing unless treatment, prevention or societal attitudes changed. Weighing these competing pros and cons could be difficult. This study, the first to use in-depth qualitative interviews to assess views of autism self-advocates regarding genetic testing, highlights key complexities. Respondents felt that such testing is neither wholly good or bad in itself, but rather may be acceptable depending on how it is used, and should be employed in beneficial, not harmful ways. These findings have important implications for practice, education of multiple stakeholders, research, and policy.
- 21 April 2024
- Published by Taylor & Francis in AJOB Empirical Bioethics
- p. 1-18
Views of Genetic Testing for Autism Among Autism Self-Advocates: A Qualitative Study
Autism self-advocates' views regarding genetic tests for autism are important, but critical questions about their perspectives arise. We interviewed 11 autism self-advocates, recruited through autism self-advocacy websites, for 1 h each. Interviewees viewed genetic testing and its potential pros and cons through the lens of their own indiviudal perceived challenges, needs and struggles, especially concerning stigma and discrimination, lack of accommodations and misunderstandings from society about autism, their particular needs for services, and being blamed by others and by themselves for autistic traits. Their views of genetic testing tended not to be binary, but rather depended on how the genetic test results would be used. Interviewees perceived pros of genetic testing both in general and with regard to themselves (e.g., by providing "scientific proof" of autism as a diagnosis and possibly increasing availability of services). But they also perceived disadvantages and limitations of testing (e.g., possible eugenic applications). Participants distinguished between what they felt would be best for themselves and for the autistic community as a whole. When asked if they would undergo testing for themselves, if offered, interviewees added several considerations (e.g., undergoing testing because they support science in general). Interviewees were divided whether a genetic diagnosis would or should reduce self-blame, and several were wary of testing unless treatment, prevention or societal attitudes changed. Weighing these competing pros and cons could be difficult. This study, the first to use in-depth qualitative interviews to assess views of autism self-advocates regarding genetic testing, highlights key complexities. Respondents felt that such testing is neither wholly good or bad in itself, but rather may be acceptable depending on how it is used, and should be employed in beneficial, not harmful ways. These findings have important implications for practice, education of multiple stakeholders, research, and policy.
- 29 December 2023
- Published by Springer Nature in Journal of Autism and Developmental Disorders
- Vol. 55 (1) , 284-296
Impact of Receiving Genetic Diagnoses on Parents’ Perceptions of Their Children with Autism and Intellectual Disability
To assess whether genetic test results identifying the cause of a child’s autism, when accompanied by other neurodevelopmental disorders (NDD), including intellectual disability, alter how parents perceive and treat their child. 28 parents of 22 individuals with autism (mean age: 15 years), usually with other NDDs, were interviewed after receiving genetic diagnoses indicating a de novo mutation through the Simons Foundation Powering Autism Research for Knowledge study. Diagnosis of a de novo genetic variant can alter parental perceptions of offspring with autism and other NDDs. Parents often blamed their child less, saw their child as less in control of symptoms, and developed more patience, framing expectations accordingly. Parents had mixed feelings about receiving genetic diagnoses, with sadness sometimes accompanying reframed expectations. Genetic diagnoses could change views of the child among extended family members, teachers, social service agencies, insurers, and broader communities and society. Genetic testing might also reduce delays in diagnoses of autism among African American, Latino and other children. These data, the first to examine several critical aspects of how parents and others view children with autism and other NDDs after receiving genetic diagnoses, highlight vital needs for education of multiple stakeholders (including geneticists, other physicians, genetic counselors, parents, individuals with autism, social service agencies, insurers, policymakers, and the broader public), research (to include perspectives of extended family members, insurers, social service agencies and teachers) and practice (to increase recognition and awareness of the potential benefits and effects of genetic testing for such children).
- 29 December 2023
- Published by Springer Nature in Journal of Autism and Developmental Disorders
- Vol. 55 (1) , 284-296
Impact of Receiving Genetic Diagnoses on Parents’ Perceptions of Their Children with Autism and Intellectual Disability
To assess whether genetic test results identifying the cause of a child’s autism, when accompanied by other neurodevelopmental disorders (NDD), including intellectual disability, alter how parents perceive and treat their child. 28 parents of 22 individuals with autism (mean age: 15 years), usually with other NDDs, were interviewed after receiving genetic diagnoses indicating a de novo mutation through the Simons Foundation Powering Autism Research for Knowledge study. Diagnosis of a de novo genetic variant can alter parental perceptions of offspring with autism and other NDDs. Parents often blamed their child less, saw their child as less in control of symptoms, and developed more patience, framing expectations accordingly. Parents had mixed feelings about receiving genetic diagnoses, with sadness sometimes accompanying reframed expectations. Genetic diagnoses could change views of the child among extended family members, teachers, social service agencies, insurers, and broader communities and society. Genetic testing might also reduce delays in diagnoses of autism among African American, Latino and other children. These data, the first to examine several critical aspects of how parents and others view children with autism and other NDDs after receiving genetic diagnoses, highlight vital needs for education of multiple stakeholders (including geneticists, other physicians, genetic counselors, parents, individuals with autism, social service agencies, insurers, policymakers, and the broader public), research (to include perspectives of extended family members, insurers, social service agencies and teachers) and practice (to increase recognition and awareness of the potential benefits and effects of genetic testing for such children).
- 14 December 2023
- Published by Wiley in Child: Care, Health and Development
- Vol. 50 (1)
Parents' views of benefits and limitations of receiving genetic diagnoses for their offspring
Background: Individuals with autism with intellectual disabilities (ID) are increasingly undergoing genetic testing, posing questions of how parents view/respond to such results.Methods: Twenty‐eight parents whose offspring had received genetic diagnoses of de novo pathogenic variants associated with autism were interviewed.Results: Genetic diagnoses parents receive concerning their offspring's autism/intellectual disabilities can be ‘double‐edged’ in several ways, having advantages, but also certain disadvantages and limitations. Benefits were medical/scientific (e.g., ending diagnostic odysseys and potentially contributing to research), emotional (e.g., relief, peace of mind and less self‐blame), cognitive, social (e.g., validation and confirmation with others – it's ‘not just in our head’) and financial (e.g., estate planning), now and in the future (e.g., preparing for possible future symptoms, development and availability of treatment and setting realistic expectations). Limitations included a lack of medical treatments related to the genetic diagnosis, a sense of finality and heightened uncertainties which can increase anxieties (e.g., concerning additional symptoms associated with genetic diagnoses and offspring's ability to live independently in the future). Overall, parents were glad to receive the results, seeing the pros outweighing the cons. Parents responded to these tensions in various ways, having mixed feelings, recognizing the trade‐offs and/or focusing on their offspring's present needs. Factors such as age of offspring at receipt of genetic diagnosis, parent's scientific background and prior views and degrees of self‐blame affected these responses.Conclusions: These data, the first to examine how parents perceive genetic diagnoses received for offspring with autism and ID through whole exome/whole genome sequencing, highlight practical medical and psychological benefits as well as limitations. These findings thus have important implications for future education, engagement of families and research. Providers should be aware of these issues, to inform and assist families, who are considering such testing, about these potential pros and cons and responses.
- 14 December 2023
- Published by Wiley in Child: Care, Health and Development
- Vol. 50 (1)
Parents' views of benefits and limitations of receiving genetic diagnoses for their offspring
Background: Individuals with autism with intellectual disabilities (ID) are increasingly undergoing genetic testing, posing questions of how parents view/respond to such results.Methods: Twenty‐eight parents whose offspring had received genetic diagnoses of de novo pathogenic variants associated with autism were interviewed.Results: Genetic diagnoses parents receive concerning their offspring's autism/intellectual disabilities can be ‘double‐edged’ in several ways, having advantages, but also certain disadvantages and limitations. Benefits were medical/scientific (e.g., ending diagnostic odysseys and potentially contributing to research), emotional (e.g., relief, peace of mind and less self‐blame), cognitive, social (e.g., validation and confirmation with others – it's ‘not just in our head’) and financial (e.g., estate planning), now and in the future (e.g., preparing for possible future symptoms, development and availability of treatment and setting realistic expectations). Limitations included a lack of medical treatments related to the genetic diagnosis, a sense of finality and heightened uncertainties which can increase anxieties (e.g., concerning additional symptoms associated with genetic diagnoses and offspring's ability to live independently in the future). Overall, parents were glad to receive the results, seeing the pros outweighing the cons. Parents responded to these tensions in various ways, having mixed feelings, recognizing the trade‐offs and/or focusing on their offspring's present needs. Factors such as age of offspring at receipt of genetic diagnosis, parent's scientific background and prior views and degrees of self‐blame affected these responses.Conclusions: These data, the first to examine how parents perceive genetic diagnoses received for offspring with autism and ID through whole exome/whole genome sequencing, highlight practical medical and psychological benefits as well as limitations. These findings thus have important implications for future education, engagement of families and research. Providers should be aware of these issues, to inform and assist families, who are considering such testing, about these potential pros and cons and responses.